News

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. 

Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company’s future. 

“I am honored to join Grenova at such an exciting time in the company’s journey,” said Hull. “Grenova is revolutionizing the way laboratories think about and use plastics—transforming single-use mindsets into sustainable, reusable solutions. I look forward to working closely with this talented team to continue driving meaningful change.” 

The addition to Grenova’s team is complemented by a new round of equity capital. The funding will be used to enhance Grenova’s automation portfolio, expand R&D capabilities, and grow the team to meet rising demand across global markets. The financing was led by Grenova investors, Peloton Equity and Hamilton Lane’s (Nasdaq: HLNE) Impact Fund II, along with other existing investors,  

“This investment affirms confidence in our vision and the market’s urgency to reduce plastic waste,” said Katherine Marrs, CEO of Grenova. “With this capital and Ted Hull on the board, we’re positioned to accelerate our mission to scale sustainable lab practices.” 

“We are excited to continue supporting Grenova’s growth,” said Ted Lundberg, Peloton Equity Managing Partner and Grenova’s Chairman. “We have worked with Ted Hull over the past 20 years and are thrilled to have him join Grenova. Ted brings a powerful blend of vision and experience that will help Grenova press its advantage as a category leader.” 

Backed by experienced leadership, a unique and patent protected product suite, strong investor confidence, and a clear vision, Grenova is working revolutionize laboratories worldwide. 

 

Read more here.

Recent News

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation

05/21/2026

Virginia Bio Announces Recipients of its 2026 Outstanding Contributions to Bioscience Award

Richmond, VA, (May 21, 2026) – Every two years, the Virginia Biotechnology Association recognizes individual Virginians for their significant contributions to bioscience and the Virginia biotechnology ecosystem.  On April 30, Scott Meza, Esq., Shareholder at Greenberg Traurig LLP, and Nikki Hastings, Ph.D., President of CvilleBioHub, were presented with the Outstanding Contributions to Bioscience Award at